Clinical Trials Sponsored by Prenome

Total 408 results

Prenome

Recruiting

OneinSeven Gestational Diabetes Genetic and Socioeconomic Risk Study

Pregnancy Complications | Pregnancy Related | Gestational Diabetes | Risk Reduction | Genetic Predisposition

United States
Second Genome

Terminated

Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis

United States
Genome & Company

Not yet recruiting

A First-in-human Study of GENA-104A16 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

Korea, Republic of
Freenome Holdings Inc.

Recruiting

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening (PROACT-LUNG)

Lung Cancer Diagnosis

United States
Freenome Holdings Inc.

Completed

AI-EMERGE: Development and Validation of a Multi-analyte, Blood-based Colorectal Cancer Screening Test

Adenoma | Polyps | Cancer, Rectum | Polyp of Colon | Colo-rectal Cancer | Adenoma Colon | Neoplasms,Colorectal | Cancer Colon

United States, Canada
Freenome Holdings Inc.

Recruiting

The Sanderson Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening

Newly-diagnosed Cancers | Non-cancer Controls

United States
Freenome Holdings Inc.

Recruiting

The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening

Cancer

United States
Freenome Holdings Inc.

Active, not recruiting

Prevention of Colorectal Cancer Through Multiomics Blood Testing (PREEMPT CRC)

Rectal Diseases | Colorectal Cancer | Adenoma | Rectal Cancer | Colon Cancer | Colon Polyp | Colon Lesion | Colon Neoplasm | Polyp | Colon Diseases | Gastrointestinal Tract Cancers

United States, United Arab Emirates
Human Genome Sciences Inc.

Completed

A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

United States, Germany, Hungary, Romania
Human Genome Sciences Inc.

Completed

Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)

Lupus Erythematosus, Systemic

United States, Canada
Human Genome Sciences Inc.

Completed

Safety and Efficacy of an Antibody to CCR5 in Individuals With HIV Who Are Not Currently on Antiretroviral Therapy

HIV Infections

United States
Human Genome Sciences Inc.

Completed

Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

United States
Human Genome Sciences Inc.

Completed

A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic

Canada, Australia, Israel, Germany, Czech Republic, France, Poland, Romania
Human Genome Sciences Inc.

Completed

Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Canada, Australia, India
Human Genome Sciences Inc.

Terminated

A Continuation Trial for Subjects With Rheumatoid Arthritis That Have Completed Protocol LBRA01

Rheumatoid Arthritis

United States, Poland
Human Genome Sciences Inc.

Completed

Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

United States
Human Genome Sciences Inc.

Completed

Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Non-Hodgkin

United States
Human Genome Sciences Inc.

Completed

A Study of Albuferon With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 or 3

Chronic Hepatitis C

Canada
Human Genome Sciences Inc.

Withdrawn

Study to Evaluate the Pharmacodynamics and Safety of HGS1025 in Patients With Ulcerative Colitis

Ulcerative Colitis
Human Genome Sciences Inc.

Completed

A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States
Human Genome Sciences Inc.

Completed

A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)

Arthritis, Rheumatoid

United States
Human Genome Sciences Inc.

Completed

A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C

Hepatitis C

United States
Human Genome Sciences Inc.

Terminated

A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies

Lymphoid Malignancies

United States, United Kingdom
Human Genome Sciences Inc.
GlaxoSmithKline

Completed

A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (BLISS-76)

Systemic Lupus Erythematosus

United States, Spain, Israel, Netherlands, Canada, Germany, Poland, Romania, Puerto Rico, Costa Rica, Belgium, Slovakia, United Kingdom, Mexico, Italy, Austria, Czech Republic, Sweden, France
Human Genome Sciences Inc.
GlaxoSmithKline

Completed

A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) (BLISS-52)

Systemic Lupus Erythematosus

Hong Kong, Taiwan, Korea, Republic of, India, Chile, Argentina, Philippines, Colombia, Brazil, Romania, Australia, Peru, Russian Federation
Novartis
Human Genome Sciences Inc.

Completed

Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients

Chronic Hepatitis C

Taiwan, Germany, Greece, Italy, Spain, United Kingdom, France, Canada, Australia, India, Poland, Thailand
GlaxoSmithKline
Human Genome Sciences Inc.

Completed

Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76

Systemic Lupus Erythematosus
Human Genome Sciences Inc.
Novartis

Completed

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3

Chronic Hepatitis C

Korea, Republic of, United States, Spain, Canada, France, Australia, Israel, Singapore, Thailand, Malaysia, Sweden, Belgium, Germany, Taiwan, Poland, Argentina, India, Puerto Rico, Brazil, Mexico, United Kingdom
Human Genome Sciences Inc.
Novartis

Completed

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients

Chronic Hepatitis C

United States, Spain, Canada, France, Australia, Italy, Israel, Poland, United Kingdom, Germany, Czech Republic, Romania, Austria, India, Puerto Rico
Human Genome Sciences Inc.
GlaxoSmithKline

Terminated

Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

United States, Mexico
Human Genome Sciences Inc.
GlaxoSmithKline

Completed

Study of Belimumab Administered Subcutaneously to Healthy Subjects

Healthy

United States
University of British Columbia
Genome British Columbia; Genome Canada; Dynacare Laboratories, Inc.

Recruiting

Integrating Pediatric Pharmacogenomic Testing Into the Canadian Health Care System

Adverse Drug Reaction (ADR)

Canada
CHU de Quebec-Universite Laval
Laval University; Genome Canada; Genome Quebec; CERSSPL

Completed

Evaluating an Online Training Program on Shared Decision-making in Prenatal Screening

Shared Decision Making

Canada
GlaxoSmithKline
Human Genome Sciences Inc.

Completed

BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115

Systemic Lupus Erythematosus

Korea, Republic of, Japan
GlaxoSmithKline
Human Genome Sciences Inc.

Completed

GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia

Systemic Lupus Erythematosus

Korea, Republic of, China, Japan
CHU de Quebec-Universite Laval
Canadian Institutes of Health Research (CIHR); Laval University; Genome British... and other collaborators

Completed

Study of the Efficacy of New Non-invasive Prenatal Tests for Screening for Fetal Trisomies Using Maternal Blood (PEGASUS)

Trisomy 21 | Trisomy 18 | Trisomy 13

Canada
Genome & Company
Merck Sharp & Dohme LLC

Recruiting

GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer

Biliary Tract Cancer

Korea, Republic of
Genome & Company
Merck KGaA, Darmstadt, Germany

Active, not recruiting

GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of
Andrew Penn
Heart and Stroke Foundation of Canada; Genome British Columbia; Bruker Daltonics and other collaborators

Completed

SpecTRA; An Observational Study of the Verification of Protein Biomarkers in Transient Ischemic Attack.

TIA

Canada
Ottawa Heart Institute Research Corporation
Genome Canada

Recruiting

Predicting Development of SCAF in Device Patients

Atrial Fibrillation

Canada
University of Pennsylvania
Human Genome Sciences Inc.

Terminated

Desensitization With Belimumab in Sensitized Patients Awaiting Kidney Transplant

Desensitization

United States
Genome & Company
Pfizer; Merck KGaA, Darmstadt, Germany

Completed

GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy

Solid Tumor | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of Head and Neck | Urothelial Carcinoma

United States
Jewish General Hospital
Exactis Innovation; Genome Quebec

Completed

Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients

Triple Negative Breast Cancer

Canada, United States
Human Genome Sciences Inc.
GlaxoSmithKline; Emergent BioSolutions

Completed

An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With Reinjection

Therapeutic Treatment of Inhalation Anthrax
Human Genome Sciences Inc.
GlaxoSmithKline; Emergent BioSolutions

Completed

A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subjects

Healthy
Novartis Pharmaceuticals
Human Genome Sciences Inc.

Terminated

Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Subjects

Chronic Hepatitis B

Taiwan, Poland, China, Hong Kong, Thailand
Cancer Trials Australia
Human Genome Sciences Inc.

Unknown

A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia

Symptomatic Waldenstroms Macroglobulinaemia

Australia
Duke University
National Human Genome Research Institute (NHGRI)

Not yet recruiting

Genomic Medicine Risk Assessment Care for Everyone - Implementation Phase (GRACE)

Liver Diseases | Cardiovascular Diseases | Cancer | Hyperthermia

United States
Duke University
National Human Genome Research Institute (NHGRI)

Active, not recruiting

A Depression and Opioid Pragmatic Trial in Pharmacogenetics (Depression Trial) (ADOPT PGx)

Depression

United States
GlaxoSmithKline
Human Genome Sciences Inc., a GSK Company

Active, not recruiting

Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy (PLUTO)

Systemic Lupus Erythematosus

Peru, United States, Spain, Argentina, United Kingdom, Poland, Canada, Russian Federation, Japan, Mexico

Clinical Trials Sponsored by Prenome

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations